English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Adult T-cell leukemia/lymphoma (ATL) was first described in 1977 as a distinct clinico‐ pathological entity with a suspected viral etiology. Subsequently, a RNA retrovirus, hu‐ man T-cell leukemia /lymphotropic virus type 1 (HTLV-1) was isolated as a carcinogenic pathogens [1]. HTLV-1 infects approximately 15 to 20 million people worldwide, with endemic areas in Japan, the Caribbean, and Africa. After prolonged latency periods, approximately 3 to 5% of HTLV-1 infected individuals will develop either ATL or other disorders such as HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP).

Adult T-Cell Leukemia/Lymphoma (ATL): Pathogenesis, Treatment and Prognosis